Allergan buys chin fat firm Kythera for $2.1bn
This article was originally published in Scrip
Executive Summary
Allergan is now geared up to treat all signs of facial aging, it claims. The Irish-headquartered firm is to buy Kythera Biopharmaceuticals and its approved submental fullness (double chin) drug Kybella (ATX-101) for $75 per Kythera share, or around $2.1bn. The drug, which has a US launch slated for the third quarter of this year, will slot neatly into Allergan's facial aesthetics portfolio, which includes Botox, and serve as a "pivotal entry point for expanding the use of facial aesthetic products in men," hopes Allergan.